JP2006305345A - Drug for relieving carbonyl stress state and peritoneal dialysate - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a drug, a dialysate, and a method for relieving peritoneal disorders accompanying a peritoneal dialysis by inhibiting carbonyl compounds from modifying protein in the peritoneum during the peritoneal dialysis. <P>SOLUTION: Carbonyl compounds formed and accumulated in a peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds formed during the sterilization and storage of the peritoneal dialysate can be eliminated by bringing the compounds into contact with the trapping agent in advance. Furthermore, it is made possible to eliminate carbonyl compounds originating in the blood of a patient which have flowed into the peritoneal cavity as the dialysis proceeds, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a peritoneal dialysis solution used for the treatment of patients with renal failure.

  Dialysis performed on patients with chronic renal failure includes hemodialysis and peritoneal dialysis. Peritoneal dialysis is a dialysis method performed by collecting dialysate in the abdominal cavity for a certain period of time, excreting waste products in the body through the peritoneum into the dialysate, and then collecting the dialysate. Peritoneal dialysis is broadly classified into intermittent peritoneal dialysis (IPD) and continuous ambulatory peritoneal dialysis (CAPD). The CAPD method is a peritoneal dialysis method in which the advantages of the IPD method are taken and the storage time of the perfusate injected into the abdominal cavity is increased, and the fluid is exchanged about four times a day.

  Peritoneal dialysis has the advantage of being simple and less time-constrained. However, if peritoneal dialysis is continued for a long period of time, the water removal capacity gradually decreases, and abdominal protein degeneration and hardening, and peritoneal fusion may occur. It is known that there is.

  Some of these causes are considered to be glucose contained in the peritoneal dialysis solution. Many of the currently used peritoneal dialysis fluids contain glucose as an osmotic pressure regulator. Glucose is unstable to heat, and partly decomposes during sterilization, and it is considered that highly reactive carbonyl compounds capable of modifying proteins are produced as degradation products. In addition, peritoneal dialysis fluid containing glucose is thought to produce and accumulate degradation products during storage after sterilization.

  In general, glucose degradation tends to occur from the neutral to the basic side. Therefore, in normal peritoneal dialysis fluid, a buffer system that gives a pH on the acidic side (pH 5.0 to 5.4) is considered in consideration of glucose stability. Often used. However, such acidic peritoneal dialysis fluids are feared for a decrease in the immune defense mechanism of peritoneal macrophages, the occurrence of peritonitis due to the entry of bacteria, and the damage to peritoneal mesothelial cells. In order to solve such conflicting problems, there has been a strong demand for the prevention of carbonyl compound formation resulting from the decomposition of glucose in the peritoneal dialysis fluid in the vicinity of neutrality, or the removal of the carbonyl compound.

  On the other hand, peritoneal dialysis fluids containing glucose at a high concentration have been developed from the viewpoint that the peritoneal dialysis fluid containing a high concentration of glucose is not preferable for the peritoneum, such as protein modification. (Patent Document 1, Non-Patent Document 1).

  Further, from the same viewpoint, a peritoneal dialysis solution using cyclodextrin (Patent Document 2), disaccharide (Patent Document 3), and amino acid (Non-Patent Document 2) instead of glucose as an osmotic pressure regulator has been proposed. Further, a peritoneal dialysis solution in which cysteine is added to suppress the degradation of glucose is also disclosed (Patent Document 4).

  All of these methods are aimed at improving the disadvantages caused by the high concentration glucose in the peritoneal dialysate.

  In patients with chronic renal failure, it has been reported that highly reactive carbonyl compounds and AGE (Advanced glycation end products) accumulate in blood and tissues regardless of the presence or absence of hyperglycemia (non-glycemic). Patent documents 3 to 6). In renal failure, non-enzymatic biochemical reactions lead to a high load of carbonyl compounds (carbon stress), and there is a pathological condition in which protein modification is enhanced. This is considered to be for modification (Non-patent Document 7). Carbonyl stress is related not only to the problem of simply changing the structure of matrix proteins such as collagen and fibronectin, but also to the enhancement of peritoneal permeability and the induction of inflammation due to the physiological activity of carbonyl compounds on various cells. I think that.

In the case of peritoneal dialysis, waste products in the blood are excreted through the peritoneum into the peritoneal dialysate. High osmotic peritoneal dialysis fluid has an action of collecting highly reactive carbonyl compounds accumulated in the blood of renal failure patients into peritoneal dialysis fluid in the peritoneal cavity through the peritoneum. Therefore, a state of carbonyl stress with a high carbonyl compound concentration in the peritoneal dialysis solution is brought about, and proteins in the abdominal cavity are subjected to carbonyl modification, and the function of the peritoneum is reduced, which is considered to be involved in the development of peritoneal sclerosis.
In fact, in peritoneal dialysis patients, it was proved from the histological examination of endothelium and mesothelium that carbonyl stress was caused by glucose introduced into the peritoneal cavity (Non-Patent Document 8, Non-Patent Document 9). , Miyata, T. et al., J. Am. Soc. Nephrol. In press, Combet, S. et al., J. Am. Soc. Nephrol. In press, Inagi, R. et al., J. Am Soc. Nephrol. In press).

Prior art document information related to the invention of the present application is shown below.
JP-A-10-94598 JP-A-8-711146 JP-A-8-131541 JP-A-5-105633 Wilkie, ME et al., Perit. Dial. Int., 17: S47-50 (1997) Faller, B. et al., Kidney Int., 50 (suppl.56), S81-85 (1996) Miyata, T. et al., Kidney Int., 51: 1170-1181 (1997) Miyata, T. et al., J. Am. Soc. Nephrol., 7: 1198-1206 (1996) Miyata, T. et al., Kidney Int., 54: 1290-1295 (1998) Miyata, T. et al., J. Am. Soc. Nephrol., 9: 2349-2356 (1998) Miyata, T. et al., Kidney Int., 55: 389-399, (1999) Yamada, K. et al., Clin. Nephrol., 42: 354-361 (1994) Nakayama, M. et al., Kidney Int., 51: 182-186 (1997)

  An object of the present invention is to provide a method for improving a disorder caused by a carbonyl compound in peritoneal dialysis, that is, a carbonyl stress state, and a dialysis solution and a drug for realizing the method. The carbonyl compound in the present invention includes a carbonyl compound derived from a patient undergoing peritoneal dialysis, a carbonyl compound produced during the production or storage of the peritoneal dialysate itself, and a carbonyl compound produced intraperitoneally during peritoneal dialysis. It becomes a target. It is an object of the present invention to minimize damage to dialysis patients caused by these carbonyl compounds.

  The present inventor has obtained the knowledge that the highly reactive carbonyl compound contained in the peritoneal dialysis fluid injected into the abdominal cavity of the patient is not only derived from the original peritoneal dialysis fluid. That is, the carbonyl compounds other than glucose in the peritoneal dialysis effluent collected from the peritoneal dialysis patient were five times before dialysis, and the increase was considered to be a blood-derived carbonyl compound (FIG. 1). Therefore, carbonyl compounds in peritoneal dialysis fluid in the peritoneal cavity are not only carbonyl compounds produced during the heat sterilization process of peritoneal dialysis fluid, or carbonyl compounds produced and accumulated during storage of peritoneal dialysis fluid, and carbonyl compounds derived from blood. It was found that the presence of the compound and the carbonyl compound produced and accumulated in the peritoneal cavity cannot be ignored. In fact, in the examination of peritoneal tissue of peritoneal dialysis patients using immunostaining, carbonyl-modified protein was localized in the tissue (FIG. 2). Therefore, if the carbonyl compound that flows out from the blood into the abdominal cavity along with peritoneal dialysis can be removed, it is presumed that the carbonyl stress state is improved more effectively.

  The present inventor has a pathological condition that enhances protein modification in vivo in renal failure, and when a high concentration of glucose is continuously injected into the abdominal cavity as in peritoneal dialysis, carbonyl compounds in the abdominal cavity accumulate. It was thought that the peritoneal dialysis solution could put the peritoneal protein more susceptible to non-enzymatic modification (FIG. 7).

  Under the background as described above, the present inventor has found that a carbonyl compound trapping agent is effective for preparing a dialysate that reduces carbonyl compounds derived from peritoneal dialysate, and has completed the present invention. Furthermore, the inventor attaches importance to carbonyl compounds accumulated in the blood, and finds that a drug capable of inhibiting peritoneal dialysis complications mainly by protein modification by carbonyl stress has found the present invention completed.

That is, the present invention relates to a carbonyl stress state ameliorating agent and a peritoneal dialysis solution applied thereto, and a drug, more specifically,
[1] An agent for improving intraperitoneal carbonyl stress state in peritoneal dialysis containing a carbonyl compound trapping agent as an active ingredient,
[2] The carbonyl stress state improving agent according to [1], wherein the carbonyl compound trapping agent is immobilized on an insoluble carrier.
[3] The carbonyl stress trapping agent according to [1], wherein the carbonyl compound trapping agent is for mixing with a peritoneal dialysis solution,
[4] The carbonyl compound trapping agent according to any one of [1] to [3], wherein the carbonyl compound trapping agent is a compound selected from the group consisting of aminoguanidine, pyridoxamine, hydrazine, SH group-containing compounds, or derivatives thereof. Carbonyl stress condition improving agent,
[5] The carbonyl stress state improving agent according to any one of [1] to [3], wherein the carbonyl compound trapping agent is a Maillard reaction inhibitor,
[6] The carbonyl stress state-improving agent according to [1], wherein the carbonyl compound trapping agent is a compound insoluble in a peritoneal dialysis solution capable of adsorbing a carbonyl compound.
[7] A cartridge for trapping a carbonyl compound in a peritoneal dialysate filled with the carbonyl compound trapping agent of [2] and / or [6],
[8] A method for preparing a peritoneal dialysate with reduced carbonyl compound content, comprising a step of passing the peritoneal dialysate through the carbonyl compound trap cartridge according to [7],
[9] A method for preparing a peritoneal dialysis solution having a reduced carbonyl compound content, comprising the following steps:
a) a step of bringing the carbonyl compound trapping agent according to [2] and / or [6] into contact with a peritoneal dialysate, and b) a step of separating the carbonyl compound trapping agent from the peritoneal dialysate [10] a carbonyl compound trapping agent Peritoneal dialysis fluid, including
[11] Peritoneal dialysis solution contained in a fractionated container consisting of a first chamber and a second chamber, wherein reducing sugar is contained in the first chamber and a carbonyl compound trapping agent is contained in the second chamber The peritoneal dialysis solution according to [10],
[12] The peritoneal dialysate according to [10], wherein the carbonyl compound trapping agent is for intraperitoneal administration together with the peritoneal dialysate,
About.

  Or this invention relates to use of the carbonyl compound trap agent in the carbonyl stress state improvement method in an abdominal cavity. The invention also relates to the use of carbonyl compound trapping agents in peritoneal dialysis treatment. Furthermore, this invention relates to use of the carbonyl compound trap agent in the manufacturing method of a carbonyl stress improving agent.

In the present invention, examples of the carbonyl compound to be trapped include a carbonyl compound produced during the peritoneal dialysate production process and during storage. As described above, peritoneal dialysis fluid containing glucose at a high concentration as an osmotic pressure regulator always has the possibility of carbonyl compound formation. As this type of carbonyl compound, for example, the following substances are known (Richard, JU et al., Fund. Appl. Toxic., 4: 843-853 (1984)).
・ 3-deoxyglucosone ・ 5-hydroxymethylfurfural (5-hydroxymethylfurfural, hereinafter abbreviated as 5-HMF)
・ Formaldehyde, acetaldehyde, glyoxal, methylglyoxal, levulinic acid, furfural, arabinose

In the present invention, the carbonyl compound trapping agent is used throughout the dialysis, so that it accumulates in the blood of patients with renal failure as well as the carbonyl compound produced during the peritoneal dialysate manufacturing process and storage, and is associated with peritoneal dialysis. Removal of the following carbonyl compounds transported into the peritoneal cavity can also be achieved.
Carbonyl compounds derived from ascorbic acid:
Dehydroascorbic acid Carbonyl compounds derived from carbohydrates, lipids, or amino acids:
・ Glyoxal,
Methyl glyoxal,
・ 3-deoxyglucosone ・ hydroxynonenal ・ malondialdehyde ・ acrolein

  As the carbonyl compound trapping agent in the present invention, it is desirable that all of the carbonyl compounds lose or reduce the modification activity of the carbonyl compound on the protein by chemical reaction or adsorption. The case where it is effective only for the main thing among compounds is also included. For example, methylglyoxal is considered to be relatively reactive among carbonyl compounds (Thornalley, RJ, Endocrinol. Metab. 3: 149-166 (1996), Inagi, R. et al., J. Am. Soc Nephrol. In press, and Example 3), depriving its activity has great pathophysiological significance. Therefore, it can be said that a compound effective against methylglyoxal is desirable as a carbonyl compound trapping agent in the present invention. Specifically, as shown in the Examples, compounds such as activated carbon, guanidine, aminoguanidine, biguanide, cysteine, and albumin are particularly effective carbonyl compound trapping agents for methylglyoxal.

  Some carbohydrates that are more stable than glucose have been reported as osmotic pressure regulators, but it is not easy to completely suppress the formation of these carbonyl compounds during heat sterilization and storage. Therefore, even when a carbohydrate other than glucose is used, the use of the carbonyl compound trapping agent is meaningful. In addition to glucose, carbohydrates that can be used as an osmotic pressure regulator for peritoneal dialysis include trehalose (JP-A-7-323084), hydrolyzed starch (JP-A-8-85701), maltitol and lactitol (JP-A-8-131541). ), Or non-reducing oligosaccharides, non-reducing polysaccharides (Japanese Patent Laid-Open No. 10-94598) and the like are known.

The carbonyl compound trapping agent in the present invention is a compound that loses or lowers the disorder activity of a carbonyl compound against a dialysis patient by chemical reaction or adsorption with the carbonyl compound. Use safe and safe materials. For example, the following compounds are known. The carbonyl compound trapping agent of the present invention may be used alone or as two or more kinds of compounding agents.
・ Aminoguanidine (Foote, EF et al., Am. J. Kidney Dis., 25: 420-425 (1995))
± 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (± 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide: OPB-9195) (S. Nakamura, 1997, Diabetes. 46: 895-899)

  Further, as the carbonyl compound trapping agent, for example, the following compounds or their derivatives, which can function as the carbonyl compound trapping agent, can be used. A derivative refers to a compound in which substitution of an atom or molecule occurs at any position of the compound.

(1) Guanidine derivatives such as methylguanidine (Japanese Patent Laid-Open Nos. 62-142114, 62-249908, 1-56614, 1-83059, 2-156, and 2-156 -765, JP-A-2-42053, JP-A-6-9380, JP-A-5-505189).
(2) Hydrazine derivatives such as sulfonylhydrazine.
(3) Pyrazolone (JP-A-6-287179), pyrazoline (JP-A-10-167965), pyrazole (JP-A-6-192089, JP-A-6-298737, JP-A-6-29838), imidazolidine ( 5-membered complex having two nitrogen atoms such as JP-A-5-201993, JP-A-6-135968, JP-A-7-133264, JP-A-10-182460), Hydantoin (JP-A-6-135968) Cyclic compounds.
(4) A 5-membered heterocyclic compound having three nitrogen atoms, such as triazole (Japanese Patent Laid-Open No. 6-192089).
(5) Thiazoline (JP-A-10-167965), thiazole (JP-A-4-9375, JP-A-9-59258), thiazolidine (JP-A-5-201993, JP-A-3-261772, JP-A-7-271) 5-membered heterocyclic compounds having one nitrogen atom and one sulfur atom, such as 133264 and JP-A-8-157473).
(6) A 5-membered heterocyclic compound having one nitrogen atom and one oxygen atom, such as oxazole (JP-A-9-59258).
(7) Nitrogen-containing 6-membered heterocyclic compounds such as pyridine (Japanese Patent Application Laid-Open Nos. 10-158244 and 10-175594) and pyrimidines (Japanese Patent Application Laid-Open No. 7-500811).
(8) Nitrogen-containing condensed heterocyclic compounds such as indazole (JP-A-6-287180), benzimidazole (JP-A-6-305964) and quinoline (JP-A-3-161441).
(9) Sulfur-containing nitrogen-containing condensed heterocyclic compounds such as benzothiazole (JP-A-6-305964).
(10) Sulfur-containing condensed heterocyclic compounds such as benzothiophene (Japanese Patent Laid-Open No. 7-196498).
(11) Oxygen-containing condensed heterocyclic compounds such as benzopyran (JP-A-3-204874 and JP-A-4-308586).
(12) Nitrogen compounds such as carbazoyl (JP-A-2-156, JP-A-2-7553), carbazic acid (JP-A-2-167264), and hydrazine (JP-A-3-148220).
(13) Quinones such as benzoquinone (JP-A-9-315960) and hydroquinone (JP-A-5-9114).
(14) Aliphatic dicarboxylic acids (JP-A-1-56614, JP-A-5-310565).
(15) Silicon-containing compound (Japanese Patent Laid-Open No. 62-249709).
(16) Organic germanium compounds (JP-A-2-62885, JP-A-5-255130, JP-A-7-247296, JP-A-8-59485).
(17) Flavonoids (JP-A-3-240725, JP-A-7-206838, JP-A-9-241165, WO94 / 04520).
(18) Alkylamines (JP-A-6-206818, JP-A-9-59233, JP-A-9-40626, JP-A-9-124471).
(19) Amino acids (Special Tables Nos. 4-502611 and 7-503713).
(20) Aromatic compounds such as ascochlorin (JP-A-6-305959), benzoic acid (WO91 / 11997), and pyrrolonaphthyridinium (JP-A-10-158265).
(21) Polypeptide (Special Table No. 7-500580).
(22) Vitamins such as pyridoxamine (WO97 / 09981).
(23) SH group-containing compounds such as glutathione, cysteine, and N-acetylcysteine.
(24) SH group-containing proteins such as reduced albumin.
(25) Tetracycline compounds (Japanese Patent Laid-Open No. 6-256280).
(26) Chitosans (Japanese Patent Laid-Open No. 9-212427).
(27) Tannins (JP-A-9-40519).
(28) A quaternary ammonium ion-containing compound.
(29) Biguanides such as phenformin, buformin, or metformin.
(30) Ion exchange resin.
(31) Inorganic compounds such as activated carbon, silica gel, alumina and calcium carbonate.

  Such compounds include compounds generally known as Maillard reaction inhibitors. Maillard reaction is a non-enzymatic saccharification reaction that occurs between reducing sugars such as glucose and amino acids and proteins. In 1912, Maillard turns brown when heating a mixture of amino acids and reducing sugars. (Maillard, LC, Compt. Rend. Soc. Biol., 72: 599 (1912)). This Maillard reaction has been studied in the field of food chemistry because it is involved in browning, aroma generation, taste, and protein denaturation that occur during heat treatment and storage of food.

  However, in 1968, glycosylated hemoglobin (HbA1c), a minute fraction of hemoglobin, was identified in vivo and increased in diabetics (Rahbar. S., Clin. Chim. Acta, 22: 296 ( 1968)), the significance of the Maillard reaction in vivo and the relationship with the onset of adult diseases such as diabetic complications and arteriosclerosis and the progress of aging have been drawing attention. And the search of the substance which inhibits such an in-vivo Maillard reaction was energetically performed, and the above-mentioned compounds were discovered as a Maillard reaction inhibitor.

  However, such Maillard reaction inhibitors can eliminate peritoneal dialysis fluid and blood-derived carbonyl compounds to improve carbonyl stress status in peritoneal dialysis patients and inhibit peritoneal dialysis complications caused by carbonyl stress. It was never known that it could be done.

  In addition, the carbonyl compound trapping agent of the present invention includes organic compounds represented by the aforementioned Maillard reaction inhibitors, polymer compounds such as ion exchange resins, and inorganic compounds such as activated carbon, silica gel, alumina, and calcium carbonate. Can be used. These compounds are carbonyl compound trapping agents that are insoluble in peritoneal dialysis fluid, and can trap carbonyl compounds by utilizing their carbonyl compound adsorption ability. Although these are known as chromatographic packing materials, they are not known to be useful in improving carbonyl stress conditions.

  Conventionally, adsorption-type blood purifiers using activated carbon have been used for blood purification during drug intoxication and hepatic coma, and various endogenous and exogenous toxins and vascular actuation that increase in the early stages of acute renal failure as multi-organ failure. It is used as an adjunct therapy for hemodialysis for the purpose of removing sex substances. However, it has never been known that such an adsorption-type blood purifier is effective for removing carbonyl compounds accumulated in the peritoneal dialysate or peritoneal cavity during dialysis.

  Japanese Patent Application Laid-Open No. 58-169458 discloses an invention relating to a peritoneal dialysis solution containing a solid particulate absorbent and a peritoneal dialysis method using the peritoneal dialysis solution. However, according to the publication, the solid particulate absorbent is added to remove creatinine and low molecular weight metabolites, and this is a carbonyl compound that accumulates in the peritoneal cavity during peritoneal dialysis fluid or during dialysis. There is no description that it is effective for removal. In addition, there is no suggestion or suggestion that the use of the peritoneal dialysis method improves the carbonyl stress state of peritoneal dialysis patients.

  The composition of the peritoneal dialysis solution as a base to which the carbonyl compound trapping agent in the present invention is added may be a known one. A general peritoneal dialysis solution is composed of an osmotic pressure regulator, a buffer, and inorganic salts. Sugars as listed above are used as the osmotic pressure regulator. As the buffer, a buffer system that gives a pH on the acidic side (pH 5.0-5.4) mainly in consideration of the stability of glucose is often used. Of course, in the case where glucose is not added to the osmotic pressure regulator, a buffer that gives a more physiological pH of around 7.0 can be used. In addition, a product form has been devised in which a buffer system for adjusting pH during use is separately packaged so that a neutral pH can be used while using glucose. In the present invention, since the carbonyl compound derived from the degradation of glucose during heat sterilization and long-term storage is removed, the pH in the neutral range, which has been difficult to prepare pharmacologically conventionally due to the degradation of glucose, is reduced. A given buffer system can be preferably used. Further, inorganic salts such as sodium chloride, calcium chloride, or magnesium chloride are usually added to the peritoneal dialysis solution. These salts are added in order to bring peritoneal dialysis closer to physiological conditions and to improve biocompatibility.

  The carbonyl compound trapping agent of the present invention can be added to such a known formulation at the time of compounding the peritoneal dialysis solution, sealed as it is, and sterilized by heating. By doing so, a preventive action can be expected for the production of carbonyl compounds from these main components accompanying heat sterilization treatment. In addition, peritoneal dialysis fluid is stored in a fractionated container consisting of a first chamber and a second chamber, reducing sugar is stored in the first chamber, a carbonyl compound trapping agent is stored in the second chamber, and mixed immediately before use. May be. In this case, the carbonyl compound produced at the time of sterilization and storage is quickly combined with the mixed carbonyl compound trapping agent. And after an intraperitoneal administration, the surplus carbonyl compound trap agent captures carbonyl compounds derived from blood. The carbonyl compound trapping agent added to the peritoneal dialysate may be used alone or in combination of two or more.

  On the other hand, various forms are conceivable as a method for contacting the peritoneal dialysis solution with the carrier in which the carbonyl compound trapping agent is immobilized or the carbonyl compound trapping agent insoluble in the peritoneal dialysis solution. For example, the peritoneal dialysate is contained in a container in which a carbonyl compound trapping agent is immobilized inside, or a container containing a carbonyl compound trapping agent immobilized on a carrier such as particles or fibers, and the carbonyl compound that is produced and accumulated during storage is stored. It can be trapped. In the latter case, the insoluble carrier can be separated from the peritoneal dialysate by filtration or the like. Also, a bead-like or fiber-like carrier on which a carbonyl compound trapping agent is immobilized, or a carbonyl compound trapping agent that is insoluble in itself is packed into a column to form a carbonyl compound trapping cartridge, and peritoneal dialysate is brought into contact with this cartridge. Later, it can be introduced into the abdominal cavity. Such a cartridge is preferably filled with distilled water or the like in advance in order to prevent air contamination at the start of peritoneal dialysis. When contacting the carbonyl compound trap cartridge at the time of peritoneal introduction, the patient-derived carbonyl compound accumulated during dialysis cannot be removed, but the carbonyl compound in the dialysate can be removed. Alternatively, in the case of the peritoneal dialysis method in which peritoneal dialysis fluid is circulated in a closed circuit using a small circulation pump, the carbonyl compound trap cartridge in which a carbonyl compound trapping agent is immobilized in the circulation circuit In addition to peritoneal dialysate, the removal of carbonyl compounds that accumulate in the abdominal cavity during dialysis can be achieved.

  The carrier for immobilizing the carbonyl compound trapping agent in the present invention is not particularly limited as long as it is harmless to the human body and has safety and stability as a material that directly contacts the peritoneal dialysis solution. Examples thereof include synthetic or natural organic polymer compounds, inorganic materials such as glass beads, silica gel, alumina, and activated carbon, and those whose surfaces are coated with polysaccharides, synthetic polymers, and the like. The carrier for immobilizing the carbonyl compound trapping agent and the carbonyl compound trapping agent that is insoluble in the peritoneal dialysis fluid are subject to substance permeation, chemical compatibility, and protective strength by applying known modification, modification, or modification. , Adsorption capacity, or specificity for carbonyl compounds.

  Examples of the carrier made of a polymer compound include a polymethyl methacrylate polymer, a polyacrylonitrile polymer, a polysulfone polymer, a vinyl polymer, a polyolefin polymer, a fluorine polymer, a polyester polymer, Examples include polyamide polymers, polyimide polymers, polyurethane polymers, polyacrylic polymers, polystyrene polymers, polyketone polymers, silicon polymers, cellulose polymers, chitosan polymers, and the like. Specifically, polysaccharides such as agarose, cellulose, chitin, chitosan, sepharose, dextran and their derivatives, polyester, polyvinyl chloride, polystyrene, polysulfone, polyether sulfone, polypropylene, polyvinyl alcohol, polyallyl ether sulfone, Examples thereof include polyacrylic acid ester, polymethacrylic acid ester, polycarbonate, acetylated cellulose, polyacrylonitrile, polyethylene terephthalate, polyamide, silicone resin, fluororesin, polyurethane, polyether urethane, polyacrylamide, and derivatives thereof. These polymer materials can be used alone or in combination of two or more. When two or more types are combined, a carbonyl compound trapping agent is immobilized on at least one of them. The carbonyl compound trapping agent to be immobilized may be immobilized alone or two or more types may be immobilized. Moreover, the above-mentioned polymer material can be used as a single polymer or a copolymer with a different polymer. Further, an appropriate modifier may be added or a modification treatment such as radiation crosslinking or peroxide crosslinking may be performed.

  There is no restriction | limiting in the shape of a support | carrier, For example, a film | membrane form, a fiber form, a granular form, a hollow fiber form, a nonwoven fabric form, a porous shape, a honeycomb shape etc. are mentioned. These carriers can control the contact area with the peritoneal dialysate by varying the thickness, surface area, thickness, length, shape, and / or size. Furthermore, a carbonyl compound trapping agent can be fixed on the inner wall of a container for containing the peritoneal dialysate or the peritoneal dialysate circulation circuit.

  In order to immobilize the carbonyl compound trapping agent on the carrier, a known method such as a physical adsorption method, a biochemical specific binding method, an ionic bonding method, a covalent bonding method, or grafting may be used. If necessary, a spacer may be introduced between the carrier and the carbonyl compound trapping agent. When elution from the carrier becomes a problem, such as when the carbonyl compound trapping agent is toxic, the carbonyl compound trapping agent is preferably immobilized on the carrier by a covalent bond in order to minimize the amount of elution. In order to covalently bond the carbonyl compound trapping agent to the carrier, a functional group present on the carrier may be used. Examples of the functional group include, but are not limited to, a hydroxyl group, an amino group, an aldehyde group, a carboxyl group, a thiol group, a hydroxyl group, a silanol group, an amide group, an epoxy group, and a succinimide group. Examples of the covalent bond include ester bond, ether bond, amino bond, amide bond, sulfide bond, imino bond, disulfide bond and the like.

  As the carrier on which the carbonyl compound trapping agent is immobilized, for example, a commercially available carrier such as a polystyrene carrier having a sulfonylhydrazine group (PS-TsNHNH2, ARGONAUT TECHNOLOGIES) can also be used.

  For sterilization of the carrier on which the carbonyl compound trapping agent is immobilized according to the present invention, an appropriate sterilization method is selected from known sterilization methods depending on the type of the carbonyl compound trapping agent and the carrier. Sterilization includes high pressure steam sterilization, gamma irradiation sterilization, gas sterilization, and the like. It is also possible to prepare a cartridge filled with an insoluble carbonyl compound trapping agent or a carbonyl compound trapping agent bound to a carrier, and sterilize both of them simultaneously while connected to a container containing peritoneal dialysis fluid.

  When the amount of the carbonyl compound trapping agent in contact with the peritoneal dialysis solution is small, it is expected that the carbonyl compound in the peritoneal dialysis solution cannot be sufficiently removed. In general, it is difficult to predict the amount of carbonyl compounds during peritoneal dialysis in advance, so it is effective to keep as many carbonyl compound trapping agents as possible within the range that can guarantee patient safety. . The dose of the carbonyl compound trapping agent can be adjusted by changing the amount of the carbonyl compound trapping agent immobilized on the carrier or the amount of the carrier on which the carbonyl compound trapping agent is immobilized.

  Alternatively, a carbonyl compound trapping agent can be injected into a peritoneal dialysis circuit equipped with an appropriate mixed injection connector. In this case, the carbonyl compound produced during sterilization and storage is captured in the circuit.

  Furthermore, a carbonyl compound trapping agent can be directly administered into the abdominal cavity and mixed with the peritoneal dialysis solution in the abdominal cavity. At this time, carbonyl compounds derived from peritoneal dialysis fluid and blood are inactivated in the peritoneal cavity.

  Moreover, the carbonyl stress state in the abdominal cavity can be improved by administering the carbonyl compound trapping agent into the peritoneal dialysis patient body by intravenous injection or the like before injecting the peritoneal dialysate into the patient or during intraperitoneal storage. .

The preferred embodiments of the peritoneal dialysis solution according to the present invention are specifically shown below.
First, the following prescription is generally used for the composition of the base dialysate. These prescriptions are just general, and in practice, a more appropriate composition is adopted according to the patient's symptoms.
Glucose 1-5% w / v
Sodium ion 100-150meq
Potassium ion 0-0.05meq
Magnesium ion 0-2meq
Calcium ion 0-4meq
Chlorine ion 80-150meq
Buffer 10-50mM
(Organic acids such as lactic acid, citric acid, malic acid, acetic acid, pyruvic acid, succinic acid)

  An effective amount of the carbonyl compound trapping agent according to the present invention is added to the basic formulation as described above. For example, when aminoguanidine is added, it is added so as to have a concentration of lmM or more, preferably 10 mM or more, more preferably 10 mM or more and 100 mM or less. When the amount added is small, the carbonyl compound trapping agent is consumed in the carbonyl compound generated during production and storage, and the carbonyl compound that is leached into the dialysate from the patient's blood or tissue during actual dialysis can be treated. A case where it cannot be expected is expected. In particular, it is difficult to predict in advance the amount of carbonyl compounds leached from the patient's blood and tissues, so it is effective to maintain as much of the carbonyl compound trapping agent as possible within the range that can guarantee patient safety. Is. Aminoguanidine is known to be low toxic to animals. According to the “Registry of Toxic Effect of Chemical Substances” (1978), the half-lethal dose of aminoguanidine is 1258 mg / kg for rats and 963 mg / kg for mice. . It is also excellent in water solubility. In addition, in the case of OPB-9195, it is similarly added so as to have a concentration of 1 mM or more, preferably 10 mM or more, more preferably 10 mM or more and 100 mM or less.

  The peritoneal dialysis solution according to the present invention blended in the above formulation is filled in a suitable sealed container and sterilized. Heat sterilization such as high-pressure steam sterilization or hot water sterilization is effective for the sterilization treatment. In this case, use a container that does not elute harmful substances at high temperatures and has strength enough to withstand transport even after sterilization. Specific examples include flexible plastic bags made of polyvinyl chloride, polypropylene, polyethylene, polyester, ethylene vinyl acetate copolymer, and the like. Further, in order to avoid deterioration of the liquid due to the influence of outside air, the container filled with the peritoneal dialysis liquid may be packaged with a packaging material having a higher gas barrier property.

  Instead of heat sterilization, filter sterilization can also be performed. For example, sterilization is performed by filtering using a microfilter equipped with a membrane filter having a pore size of about 0.2 μm. In this case, generation of a carbonyl compound derived from heating can be prevented. The peritoneal dialysate sterilized by filtration is filled in a container such as a flexible plastic bag and then sealed. Since a series of processes from sterilization to transportation is not different from the current production of dialysate, the peritoneal dialysate according to the present invention can be produced in the same process.

  When sterilization is carried out by heat sterilization including high-pressure heat sterilization, if the carbonyl compound trapping agent used is sufficiently stable against heating and other treatments, the carbonyl compound trapping agent should be added in advance when the peritoneal dialysis solution is blended. Thus, a heat sterilization operation can be performed. In this way, the production / accumulation of carbonyl compounds derived from the dialysate during heating can be suppressed. Of course, the carbonyl compound trapping agent functions during storage and during peritoneal dialysis, and the production and accumulation of carbonyl compounds can be suppressed.

  If the carbonyl compound trapping agent used is not stable to heat sterilization, a sterilization method that does not require heating can also be used. Such sterilization methods include, for example, filter sterilization. In addition, the carbonyl compound trapping agent may be added later to the peritoneal dialysis solution that has been pre-sterilized by heating. There is no particular limitation on the timing of addition. For example, it is preferable to add the carbonyl compound trapping agent after sterilizing the liquid, because it can suppress the generation and / or accumulation of carbonyl compounds not only during peritoneal dialysis but also during storage of peritoneal dialysis fluid before dialysis. .

Alternatively, the carbonyl compound trapping agent can be added immediately before or simultaneously with peritoneal dialysis. For example, the base solution and the carbonyl compound trapping agent are separately stored in the aforementioned soft plastic bag or the like until immediately before use, and both are aseptically mixed immediately before the start of peritoneal dialysis. For this purpose, a flexible plastic bag partitioned by a peelable adhesive portion as disclosed in JP-A-63-19149 is preferably used.
Alternatively, a connector member for mixed injection may be provided in the middle of the peritoneal dialysis circuit, and the carbonyl compound trapping agent may be injected from the connector.
Such a method for preparing a peritoneal dialysis solution can be used not only for a thermally unstable carbonyl compound trapping agent but also for a heat stable carbonyl compound trapping agent.
Furthermore, in the case of the peritoneal dialysis method in which peritoneal dialysis fluid is circulated in a closed circuit using a small circulation pump, filtration with a carbonyl compound trapping agent filled in any part of the circuit. A vessel can also be installed.

  The peritoneal dialysis solution of the present invention is used for the peritoneal dialysis treatment similar to the current peritoneal dialysis solution. That is, an appropriate amount of the peritoneal dialysis solution according to the present invention is injected into the abdominal cavity of a dialysis patient, and low molecular weight components in the living body are transferred into the peritoneal dialysis solution through the peritoneum. Peritoneal dialysate is circulated intermittently and dialysis is continued according to the patient's symptoms. At this time, the carbonyl compound moves from the blood or the peritoneum into the peritoneal dialysis solution together with dialysis components such as creatinine, inorganic salts, or chloride ions. At the same time, due to the action of the carbonyl compound trapping agent, its damaging activity on the living body is improved and rendered harmless.

  EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not restrict | limited by these Examples.

[Example 1] Measurement of amount of carbonyl compound in peritoneal dialysis fluid and peritoneal dialysis drainage To prove the occurrence of carbonyl stress in the peritoneal cavity, the amount of carbonyl compound in peritoneal dialysis drainage was measured according to the following experimental method. .

1) Measurement of carbonyl compound The peritoneal dialysis solution (Baxter, Die-annealing PD-2 2.5) and the peritoneal dialysis solution are administered to peritoneal dialysis patients, and 400 μL of peritoneal dialysis drainage after overnight storage in the abdominal cavity is taken to 1.5 mM. 2,4-dinitrophenylhydrazine (2,4-DNPH) (manufactured by Wako Pure Chemical Industries, Ltd.) was mixed with 400 μL of 0.5N hydrochloric acid solution and stirred at room temperature for 30 minutes. The carbonyl compound and 2,4-DNPH in the liquid were then mixed. Reacted. Next, 40 μL of 1M acetone aqueous solution was added, and the mixture was stirred at room temperature for 5 minutes to remove excess 2,4-DNPH by reacting with acetone, and then washed with 400 μL n-hexane three times. The absorbance was measured with a spectrophotometer for microplate (SPECTRAmax250 manufactured by Nihon Molecular Devices Co., Ltd.).

2) Preparation of calibration curve Glucose aqueous solutions having various concentrations were prepared, and a calibration curve for glucose and the amount of carbonyl compound derived from glucose was prepared in the same manner as in 1).

3) Quantification of carbonyl compound The glucose concentration in the peritoneal dialysis fluid and peritoneal dialysis effluent was measured using a glucose measurement kit (manufactured by Wako Pure Chemical Industries, glucose CII-Test Wako). The amount of glucose-derived carbonyl compound was determined from the calibration curve. The amount of carbonyl compound derived from glucose was subtracted from the amount of total carbonyl compound in the liquid to obtain the amount of carbonyl compound.

  The obtained results are shown in FIG. In the peritoneal dialysis drainage after being stored overnight in the abdominal cavity, the amount of carbonyl compound was about 5 times that in the peritoneal dialysis fluid before administration, indicating the transfer of the carbonyl compound from the blood into the peritoneal cavity.

[Example 2] Systematic localization of carbonyl-modified protein in the peritoneum of peritoneal dialysis fluid patients The carbonyl compounds in the peritoneal tissue of peritoneal dialysis patients were examined by immunostaining using malondialdehyde as an index.

  According to the method of Horie et al. (Horie, K. et al., J. Clin. Invest., 100, 2995-3004 (1997)) Immunostaining was performed using mouse anti-malondialdehyde monoclonal antibody as the primary antibody. As a result, strong positive findings were observed in the connective tissue under the detached mesothelial cells and the thickened blood vessel wall (FIG. 2).

  Malondialdehyde (MDA) is a carbonyl compound produced by the decomposition of lipid peroxide. Therefore, the results of immunostaining in the same manner using 4-hydroxy-2-nonenal, a lipid peroxide degradation product other than MDA, and antibodies against carboxymethyllysine and pentosidine produced as a result of the sugar oxidation reaction, The same part as the positive part indicated by 2 was positive. From this, it was found that peritoneal tissues of peritoneal dialysis patients were subjected to protein modification due to increased carbonyl stress caused by carbonyl compounds derived from lipid peroxide degradation products and sugar oxidation products.

[Example 3] Peritoneal cell damage due to methylglyoxal The decrease in peritoneal ultrafiltration function by long-term peritoneal dialysis is evidence of an increase in the surface area of the peritoneum that can be exchanged by diffusion (Krediet, RT, 1999, Kidney Int. 55: 341-356; Heimburger, O. et al., 1990, Kidney Int 38: 495-506; Imholz, AL et al., 1993, Kidney Int. 43: 1339-1346; Ho-dac -Pannekeet, MM et al., 1997, Perit. Dial. Int. 17: 144-150). That is, the glucose in the peritoneal dialysis fluid diffuses and flows out of the peritoneal cavity, thereby reducing the dialysis function due to the osmotic pressure gradient. This can also be explained by an increase in vascular surface area in the peritoneum. In this pathological condition, vascular endothelial growth factor (VEGF) is thought to play an important role. VEGF enhances vascular permeability (Senger, DR et al., 1983, Science 219: 983-985; Connolly, DT et al., 1989, J. Biol. Chem. 264: 20017-20024) Stimulates synthesis and dilates blood vessels (Hood, JD et al., 1998, Am. J. Physiol. 274: H1054-1058) and induces an inflammatory response (Clauss, M. et al., 1990, J. Exp Med. 172: 1535-1545; Melder, RJ et al., 1996, Nat. Med. 2: 992-997). VEGF is also a potent angiogenic factor and has a function of restoring vascular injury (Thomas, KA, 1996, J. Biol. Chem. 271: 603-606; Ferrara, N. et al., 1997, Endocr Rev. 18: 4-25; Shoji, M. et al., 1998, Am. J. Pathol. 152: 399-411). Therefore, the effect of glucose degradation products contained in the dialysate on VEGF production was verified.

<3-1> Expression of VEGF in peritoneal mesothelial and vascular endothelial cell cultures in the presence of glucose degradation products Peritoneum was collected from 6-week-old male CD (SD) IGS rats (Charles-River, Kanagawa, Japan) . Mesothelial cells were isolated based on the method of Hjelle et al. (Hjelle. JT et al., 1989, Perit. Dial. Int. 9: 341-347) and Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum Incubated in Seven to ten passage mesothelial cells were separated from various concentrations of glucose degradation products (glyoxal, methylglyoxal (Sigma, St. Louis, MO)) or 3-deoxyglucosone (Fuji Memorial Research Institute, Otsuka Pharmaceutical Co., The cells were cultured for 3 hours in a CO ₂ incubator in the presence of Kyoto). Analysis of VEGF mRNA expression was performed by semi-quantitative RT-PCR. Total RNA was isolated from mesothelial cells using the Rneasy Mini Kit (Qiagen, Germany). 5 μg of RNA was reverse transcribed using oligo (dT) _12-18 primer (Gibco BRL, Gaithersburg, MD) and 200 units of RNase H-free reverse transcriptase (Superscript II: Gibco BRL), and PCR amplification was described previously. (Miyata, T. et al., 1994, J. Clin. Invest. 93: 521-528). The oligonucleotide primer sequence used was 5'-ACTGGACCCTGGCTTTACTGC-3 '(SEQ ID NO: 1) and 5'-TTGGTGAGGTTTGATCCGCATG-3' (SEQ ID NO: 2) for the primer used for amplification of rat VEGF, and was amplified by 310 bp. The product was obtained. The primers used for amplification of rat glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were 5′-CCTGCACCACCAACTGCTTAGCCC-3 ′ (SEQ ID NO: 3) and 5′-GATGTCATCATATTTGGCAGGTT-3 ′ (SEQ ID NO: 4), and 322 bp The fragment was amplified. G3PDH was used as an internal standard for RNA, and RNA levels were compared between different samples. For each sample, an appropriate number of cycles was first determined using a DNA thermal cycler (Perkin Elmer Cetus, Norwork, CT) under conditions of 94 ° C. for 0.5 minutes, 60 ° C. for 1 minute, and 72 ° C. for 1.5 minutes. As a preliminary experiment, reverse transcription and PCR amplification were performed under conditions of 16, 18, 21, 25, 28, 31, and 34 cycles with varying amounts of RNA. As a result, a signal of a PCR product quantitatively correlated with the added RNA was obtained under the conditions of 30 cycles for VEGF mRNA amplification and 21 cycles for G3PDH mRNA amplification. PCR products were electrophoresed on a 1.5% agarose gel, stained with ethidium bromide, and then quantified by measuring the signal intensity with a quantification program (NIH image). Experiments were performed at each glucose degradation product concentration. MRNA was quantified in triplicate experiments and the average of each experiment was determined. A total of 3-4 independent experiments were performed under each experimental condition. The results were averaged and expressed as mean ± SD. Statistical significance was assessed by analysis of variance (ANOVA). When this analysis showed a significant difference, the results obtained at different methylglyoxal concentrations were compared by the Scheffe t-test.

  At various concentrations from 0 to 400 μM, glyoxal and 3-deoxyglucosone did not alter VEGF expression (FIGS. 3A and B). Only methylglyoxal stimulated VEGF mRNA expression at a concentration of 400 μM (P <0.0005) (FIG. 3C). No PCR product was generated from RNA samples that were not reverse transcribed. All cells were viable. When mesothelial cells were cultured in the presence of high concentrations of 3-deoxyglucosone (0.625, 2.5, and 5 mM), cell viability was reduced (cell viability was 0.625, 2.5, 5 mM) 80, 55, 8% in the presence of 3-deoxyglucosone). Due to decreased cell viability, VEGF mRNA expression could not be measured. From these observation results, only methylglyoxal was used in the following experiments.

  Release of VEGF protein into the culture supernatant of human microvascular endothelial cells cultured for 24 hours in the presence of various concentrations of methylglyoxal was measured by ELISA. Human microvascular endothelial cells were purchased from Kurabo (Osaka, Japan) and cultured in VEGF-deficient EGM-2 medium (Takara, Tokyo, Japan). Incubation with methylglyoxal was carried out in the same manner as the above rat peritoneal mesothelial cells. VEGF protein was quantified by enzyme-linked immunosorbent assay (ELISA) using the kit (Quantikine: R & D Systems, Minneapolis, USA) according to the attached instruction to the culture supernatant prepared in duplicate. The experiment was repeated three times and the results were statistically analyzed as described above.

  As a result, an increase in VEGF was observed in a dose-dependent manner by adding methylglyoxal to the medium (FIG. 4). In the absence of methylglyoxal, no release of VEGF was detected. That is, it was shown that VEGF production / release is stimulated at a protein level in a dose-dependent manner.

  Next, the expression of VEGF mRNA in endothelial cells cultured in the presence of various concentrations (0 to 400 μM) of methylglyoxal was examined. The experiment was performed in the same manner as in the case of rat mesothelial cells. However, 5′-GGCAGAATCATCACGAAGTGGTG-3 ′ (SEQ ID NO: 5) and 5′-CTGTAGGAAGCTCATCTCTCC-3 ′ (SEQ ID NO: 6) primers were used for amplification of human VEGF, and the amplified fragment was 271 bp. . The same primers were used for amplification of human G3PDH as in rats. As a result of the analysis, it was found that the expression of VEGF mRNA increases in a dose-dependent manner (FIG. 5).

<3-2> Expression of VEGF in the peritoneal tissue of rats administered intraperitoneally with methylglyoxal To investigate the biological effect of methylglyoxal on the expression of VEGF mRNA in the peritoneum in vivo An experiment was conducted in which an appropriate amount of methylglyoxal was administered for 10 days. Six week old male CD (SD) IGS rats were given 50 ml / kg of saline containing various concentrations of methylglyoxal intraperitoneally daily for 10 days. The peritoneum was isolated from the abdominal wall and examined for VEGF mRNA expression. The experiment was performed in the same manner as the in vitro experiment of rat mesothelial cells. However, ISOGEN (Nippon Gene, Tokyo, Japan) was used to extract mRNA from peritoneal tissue. PCR amplification was performed under 28 cycles for VEGF mRNA amplification and 16 cycles for G3PDH mRNA amplification.

  As shown in FIG. 6, VEGF mRNA expression in the abdominal wall peritoneum sample was significantly increased by the methylglyoxal concentration (P <0.05). Light microscopic observation showed no change in peritoneal tissue (vessel number, vessel wall, gap, and mesothelial cells were normal).

<3-3> Immunostaining of VEGF and carboxymethyllysine (CML) in peritoneal tissues of long-term peritoneal dialysis patients The distribution of VEGF and carboxymethyllysine in the peritoneal tissues of nine peritoneal dialysis patients was examined by immunohistochemical analysis. Carboxymethyllysine is derived from glucose degradation products such as glyoxal and 3-deoxyglucosone (Miyata, T. et al., 1999, Kidney Int. 55: 389-399). Accordingly, anti-carboxymethyllysine antibodies are used as markers for proteins modified with glucose degradation products.

  After obtaining informed consent, peritoneal tissue was isolated from nine non-diabetic peritoneal dialysis patients at the time of catheter re-insertion (Table 1). The need for re-insertion of the catheter arises from catheter damage, misalignment, and / or occlusion. There were no patients with peritonitis. Normal peritoneal tissue was isolated at the time of abdominal incision from two men (48 and 58 years) with normal renal function.

2μ thick peritoneal tissue sections were mounted on slides coated with 3-aminopropyltriethoxysilane (Signa), deparaffinized, passed through distilled water, and then containing Pronase (0.5mg / μl: Dako, Glostrup, Denmark) The mixture was incubated with a buffer solution (0.05 M Tris-HCl (pH 7.2), 0.1 M NaCl) at room temperature for 15 minutes. Slides were washed with PBS containing 0.5% Tween 20, blocked with 4% skim milk for 2 hours, and then anti-VEGF rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-AGE mouse IgG (Ikeda, K. et al., 1996, Biochemistry 35: 8075-8083) (with carboxymethyllysine as an epitope: Miyata, T. et al., 1997, Kidney Int. 51: 1170-1181) at 4 ° C. overnight. Incubated in Humid chamber. After washing the sections, incubate with 1: 100 dilution of peroxidase-conjugated goat anti-rabbit IgG or peroxidase-conjugated goat anti-mouse IgG (Dako) for 2 hours at room temperature and 3,3'-diaminobenzidine solution containing 0.003% H ₂ O ₂ A signal was detected. In addition, histological analysis was performed by periodic acid-Schiff staining. Immunostaining was observed independently by two people, and signal intensity and distribution were evaluated.

  The results are shown in Table 1. In the table, “normal 1” and “normal 2” represent samples from subjects with normal renal function, and “PD1” to “PD9” represent samples from peritoneal dialysis patients. Observation of a peritoneal histology (PD6 in Table 1) of a representative long-term peritoneal dialysis patient showed interstitial fibrosis, vascular wall thickening and hyaline. VEGF and carboxymethyllysine co-localized in mesothelial cells and blood vessel walls. In the mesothelial layer, the VEGF signal was weaker than the carboxymethyllysine signal. The results were similar for the other 8 patients. In the normal peritoneal sample (normal 2 in Table 1), VEGF was present only in the blood vessel wall and not detected in the mesothelial layer as compared to the peritoneal dialysis sample. Carboxymethyllysine was not detected in the mesothelial layer, and the signal of the blood vessel wall was extremely weak. These observations were similar for other control normal samples. When normal mouse IgG was used, no immunostaining was detected. Thus, only in peritoneal dialysis patients, co-localization of VEGF expression and carboxymethyllysine is seen in the mesothelium, because the peritoneal dialysis results in the degradation of glucose in the peritoneal dialysate in uremic patients. This suggests that VEGF production is enhanced.

  The above results confirm that peritoneal dialysis patients are placed in a carbonyl stress state due to glucose degradation products in peritoneal dialysate, and that methylglyoxal enhances VEGF production in peritoneal cells. For the first time. It is suggested that at least a part of the cause that the glucose degradation product contained in the peritoneal dialysate decreases the permeability of the peritoneum is due to the enhancement of VEGF production and the accompanying stimulation of angiogenesis.

[Example 4] Effect of addition of carbonyl compound trapping agent on dialysis fluid drainage of peritoneal dialysis patient <4-1>
Pentosidine is one of the structures of AGE, and about 20-fold accumulation in the blood of patients with renal failure compared to healthy individuals (Miyata, T. et al., J. Am. Soc) Nephrol., 7: 1198-1206 (1996)). We examined the effect of aminoguanidine addition on pentosidine and carbonyl groups (protein carbonyls) present on proteins, which increased when the effluent of peritoneal dialysis patients was incubated at 37 ° C.

  After overnight perfusion of peritoneal dialysis patients, the supernatant was sterilized by filtration (pore size 0.45 μm), and aminoguanidine (manufactured by Tokyo Chemical Industry) was added to a concentration of 0, 1, 10, 100 mM, 37 Incubated at 0 ° C. The incubation period was 1 to 2 weeks when pentosidine was measured, and 2 weeks when protein carbonyl was measured. Pentosidine was measured by hydrolyzing protein in 6N HCl at 110 ° C., and then quantified by HPLC (Shimadzu Corporation, LC-10A) (T.Miyata et al., 1996, J. Am. Soc. Nephrol, 7: 1198 -1206, T. Miyata et al., 1996, Proc. Natl. Acad. Aci. USA, 93: 2353-2358). Protein carbonyl was measured by reacting with 2,4-dinitrophenylhydrazine (2,4-DNPH) (manufactured by Wako Pure Chemical Industries, Ltd.) and then measuring the absorbance of hydrazone produced by reacting with the carbonyl group (manufactured by Nippon Molecular Devices). , SPECTRAmax 250) (Levine, RL et al., Methods Enzymol., 233, 346-357 (1994)).

  As a result, the inhibitory effect of aminoguanidine on the production of pentosidine was confirmed in a concentration-dependent manner (FIG. 8). Similarly, the inhibitory effect of aminoguanidine on the production of protein carbonyl was observed in a concentration-dependent manner (FIG. 9).

<4-2>
Next, the effect of aminoguanidine addition on the amount of carbonyl compounds other than glucose in the overnight effluent of peritoneal dialysis patients was examined according to the following experimental method.

(A) Incubation of peritoneal dialysis drainage After collecting peritoneal dialysis patient drainage and filtering through a 0.45μm pore size filter, aminoguanidine (manufactured by Tokyo Chemical Industry Co., Ltd.) was adjusted to concentrations of 0, 10, 50 and 250 mM. And a sample solution. 1 ml of the sample solution was taken and dispensed into a plastic tube with a screw cap, and then incubated at 37 ° C. for 15 hours. The sample solution was stored at −30 ° C. until immediately before incubation.

(B) Determination of carbonyl compounds
1) Measurement of the sample solution Take 400 μL of the sample solution, mix 1.5 mM 2,4-DNPH (manufactured by Wako Pure Chemical Industries) with 400 μL of 0.5N hydrochloric acid solution, and stir at room temperature for 30 minutes to obtain the carbonyl compound in the sample solution. 2,4-DNPH was reacted. Next, after adding 40 μL of 1M aqueous acetone solution and stirring for 5 minutes at room temperature to remove excess 2,4-DNPH by reacting with acetone, the sample solution was washed with 400 μL n-hexane three times. Absorbance at 360 nm of the aqueous layer was measured with a spectrophotometer for microplate (SPECTRAmax250 manufactured by Nihon Molecular Devices).
2) Preparation of calibration curve Glucose aqueous solutions having various concentrations were prepared, and a calibration curve for glucose and the amount of carbonyl compound derived from glucose was prepared in the same manner as in 1).
3) Quantification of carbonyl compound The glucose concentration in the sample solution was measured using a glucose measurement kit (manufactured by Wako Pure Chemical Industries, Glucose CII-Test Wako). The amount of carbonyl compound derived from glucose was determined from the calibration curve. The amount of carbonyl compound derived from glucose was subtracted from the amount of total carbonyl compound in the peritoneal dialysis effluent to obtain the amount of carbonyl compound.
The result is shown in FIG. The amount of carbonyl compounds other than glucose in the peritoneal dialysis fluid drainage of peritoneal dialysis patients decreased as the aminoguanidine concentration increased in both the unincubated and incubated at 37 ° C for 15 hours.

  From these results, it is effective to add a carbonyl compound trapping agent to the peritoneal dialysis solution or administer it to the patient in order to suppress the formation and / or accumulation of carbonyl compounds in the peritoneal dialysis solution injected into the peritoneal cavity. It became clear that there was. Thereby, carbonyl compounds derived from peritoneal dialysis fluid and blood existing in the abdominal cavity are removed, and the carbonyl stress state of the peritoneal dialysis patient is improved.

[Example 5] Effect of addition of carbonyl compound trapping agent during heat sterilization of peritoneal dialysate The peritoneal dialysate contains high concentration (1.35-4.0 w / v%) glucose as an osmotic pressure regulator. Yes. Glucose is unstable to heat and degrades during heat sterilization and storage. It has been reported that 5-hydroxymethylfurfural (5-HMF), levulinic acid, acetaldehyde and the like are produced as degradation products of glucose (Richard, JU et al., Fund. Appl. Toxic., 4: 843-853 (1984), Nilsson, CB et al., Perit. Dial. Int., 13: 208-213 (1993)). The inhibitory effect of aminoguanidine on the formation of carbonyl compounds during the heat sterilization process of peritoneal dialysate was examined by measuring the amounts of 5-HMF and carbonyl compounds. Since the degree of glucose degradation is affected by the pH of the solution, two types of peritoneal dialysis solutions were prepared with acidic (pH 5.3) and neutral (pH 7.0) pH before sterilization. Provided. The sterilization temperature was 121 ° C.

<5-1>
5-HMF was measured using high performance liquid chromatography (Shimadzu, LC-10A) (Nilsson, CB et al., Perit. Dial. Int., 13: 208-213 (1993)) .
As a result, in both acidic environment (FIG. 11) and neutral environment (FIG. 12), the inhibitory effect of aminoguanidine on the production of 5-HMF was recognized in a concentration-dependent manner.

<5-2>
The carbonyl compound in the peritoneal dialysis solution was quantified by reacting with 2,4-DNPH as in Example 1 and then measuring the absorbance (Levine, RL et al., Methods Enzymol., 233: 346-357 (1994)). The sterilization temperature was 121 ° C.
As a result, with regard to the amount of the carbonyl compound, the inhibitory effect of aminoguanidine was recognized in a concentration-dependent manner (FIG. 13).

  From these results, it is clear that the addition of an agent that suppresses the formation of carbonyl compounds in the peritoneal dialysate is very effective in suppressing the formation and / or accumulation of carbonyl compounds in the peritoneal dialysate. became.

[Example 6] Effect of addition of carbonyl compound trap beads on the formation of pentosidine in peritoneal dialysis fluid Using a crosslinked polystyrene resin bonded with a sulfonyl hydrazine group (PS-TsNHNH2, ARGONAUT TECHNOLOGIES) as a carbonyl compound trap bead, The removal effect of carbonyl compounds in peritoneal dialysate was examined. Peritoneal dialysate and peritoneal dialysate added with carbonyl compound trap beads were incubated at 37 ° C. to confirm the effect of inhibiting the formation of pentosidine. After adding 100 μl of dimethyl sulfoxide to the tube containing the carbonyl compound trap beads and swelling, add 800 μL of peritoneal dialysis solution (Baxter, Die annealing PD-4,1.5), 200 μL of 150 mg / mL bovine serum albumin dissolved in water. Added and incubated at 37 ° C. for 1 week. After completion of the incubation, the beads were removed using a centrifugal filter tube (manufactured by Millipore, UFC30GV00) having a pore size of 0.22 μm. Next, 50 μl of 10% trichloroacetic acid was added to 50 μl of the solution from which the beads had been removed, and the protein was precipitated by centrifugation. The protein was washed with 300 μl of 5% trichloroacetic acid and allowed to dry. Next, 100 μl of 6N HCl was added and heated at 110 ° C. for 16 hours, and then pentosidine was quantified by HPLC (T. Miyata et al., 1996, J. Am. Soc. Nephrol., 7: 1198-1206, T, Miyata et al., 1996, Proc. Natl. Acad. Sci. USA, 93: 2353-2358).

  The amount of pentosidine produced when incubated at 37 ° C. is shown in FIG. It has been found that the addition of carbonyl compound trap beads significantly suppresses the formation of pentosidine.

[Example 7] Effect of addition of carbonyl compound trap beads on amount of carbonyl compound in peritoneal dialysate The effect of removing carbonyl compounds in the peritoneal dialysate by carbonyl compound trap beads was examined. To a tube containing carbonyl compound trap beads (PS-TsNHNH2, ARGONAUT TECHNOLOGIES), add 100 μl of dimethyl sulfoxide to swell, then add 900 μL of peritoneal dialysis solution (Baxter, Die anneal PD-4,1.5), and add the rotator. And stirred at room temperature for 16 hours. Next, the suspension containing the carbonyl compound trap beads was filtered through a centrifugal filter tube (manufactured by Millipore, UFC30GV00) having a pore size of 0.22 μm, and the amount of the carbonyl compound in the filtrate was measured as follows.

<Quantitative determination of carbonyl compounds>
1) Measurement of sample solution After mixing 200 µL of the sample solution and 200 µL of 2,4-DNPH in 0.5N hydrochloric acid (0.025%), the mixture was reacted at 30 ° C for 30 minutes. Next, 20 μL of 1 M aqueous acetone solution was added, incubated at 30 ° C. for 10 minutes, and then washed 3 times with 200 μL n-hexane. Furthermore, 200 μL of octanol was added to the aqueous layer to extract hydrazone, and the absorbance at 360 nm of the octanol layer was measured with a spectrophotometer for microplate (SPECTRAmax250 manufactured by Nihon Molecular Devices).
2) Preparation of calibration curve Glucose aqueous solutions having various concentrations were prepared, and a calibration curve for glucose and the amount of carbonyl compound derived from glucose was prepared in the same manner as in 1).
3) Determination of amount of carbonyl compound The glucose concentration in the sample solution was measured using a glucose measurement kit (Wako Pure Chemical Industries, glucose CII-Wako). The amount of carbonyl compound derived from glucose was determined from the calibration curve. The amount of carbonyl compound derived from glucose was subtracted from the total amount of carbonyl compound in the sample solution to obtain the amount of carbonyl compound in the sample solution.
The result is shown in FIG. By adding 2 mg of carbonyl compound trap beads to the peritoneal dialysate and stirring at room temperature for 16 hours, the amount of carbonyl compound was reduced by 55%. In addition, when the amount of carbonyl compound trap beads added was increased to 10 mg, the amount of carbonyl compound further decreased. .

  From these results, it became clear that the production and / or accumulation of the carbonyl compound in the peritoneal dialysis fluid can be suppressed using the carrier on which the carbonyl compound trapping agent is immobilized.

Example 8 Carbonyl Compound Trapping Action in Dicarbonyl Solution by Activated Carbon Activated carbon was used as a carbonyl compound trapping agent, and the removal effect of carbonyl compounds in the dicarbonyl solution was examined. To a tube containing 25 μg or 50 μg of activated carbon (manufactured by Wako Pure Chemical Industries, Ltd.), 900 μl each of a dicarbonyl solution in which a dicarbonyl compound was dissolved in a phosphate buffer solution (hereinafter abbreviated as PBS) (both 100 μM) was dispensed. As the dicarbonyl compound, glyoxal, methylglyoxal, and 3-deoxyglucosone were used. The tube was set on a rotator and stirred at room temperature for 19 hours. After stirring, the solution in the tube was filtered through a centrifugal filter tube (Millipore, UFC30GV00) having a pore size of 0.22 μm, and the concentration of each dicarbonyl compound was measured using high performance liquid chromatography. The measuring method followed a known method.

  The results are shown in FIG. When 25 μg of activated carbon was added to 900 μl of dicarbonyl solution, 71% of glyoxal (GO), 94% of methylglyoxal (MGO), and 93% of 3-deoxyglucosone (3DG) were trapped by activated carbon. When 50 μg of activated carbon was used, it was confirmed that most of all the dicarbonyl compounds tested were trapped by activated carbon, 85% for glyoxal and 98% for methylglyoxal and 3-deoxyglucosone.

Example 9 Carbonyl Compound Trapping Action in Peritoneal Dialysate by Activated Carbon Using activated carbon as a carbonyl compound trapping agent, the removal effect of carbonyl compounds in the peritoneal dialysate was examined. To a tube containing 25 μg or 50 μg of activated carbon (manufactured by Wako Pure Chemical Industries, Ltd.), 900 μl of peritoneal dialysate (manufactured by Baxter, Die Annealed PD-4, 1.5, trade name) was dispensed. The tube was set on a rotator and stirred at room temperature for 19 hours. After agitation, the peritoneal dialysis solution in the tube is filtered through a 0.22 μm pore-type centrifugal filter tube (Millipore, UFC30GV00), and the concentration of glyoxal, methylglyoxal, and 3-deoxyglucosone contained in the filtrate is analyzed by high performance liquid chromatography. It measured using. The measuring method followed a known method.

  The results are shown in FIG. When 25 μg of activated carbon is added to 900 μl of peritoneal dialysis solution, 56% of glyoxal (GO), 71% of methylglyoxal (MGO), and 3-deoxyglucosone (3DG) are compared to the peritoneal dialysis solution without activated carbon. 62% were trapped by activated carbon. When 50 μg of activated carbon was used, it was confirmed that 64% of glyoxal, 78% of methylglyoxal, and 77% of 3-deoxyglucosone were trapped by activated carbon.

[Example 10] Trap effect of guanidine, aminoguanidine, and biguanide on glyoxal, methylglyoxal, and 3-deoxyglucosone 50 g of mixed solution of glyoxal, methylglyoxal, and 3-deoxyglucosone (each 1 mM), 0.1 M phosphoric acid 400 μl of buffer solution (pH 7.4), 50 μl of 30 mM guanidine, aminoguanidine, or biguanide solution were mixed and incubated at 37 ° C. As the biguanide, metformin, buformin, and phenformin were used. After completion of the incubation, glyoxal, methylglyoxal, and 3-deoxyglucosone were converted into quinoxaline derivatives using o-phenylenediamine, and the respective concentrations were measured using high performance liquid chromatography.

  The results are shown in FIG. 18 (guanidine), FIG. 19 (metformin), FIG. 20 (buformin), FIG. 21 (phenformin), and FIG. 22 (aminoguanidine). It was confirmed that guanidine, aminoguanidine, and any biguanide agent particularly remarkably reduce the concentration of methylglyoxal. In aminoguanidine, the concentration is drastically decreased with respect to methylglyoxal, and also with respect to 3-deoxyglucosone, which did not show a significant concentration-reducing effect with other biguanides. .

Example 11 Trapping effect of SH agent on glyoxal, methylglyoxal, 3-deoxyglucosone 50 μl of a mixed solution of glyoxal, methylglyoxal, 3-deoxyglucosone (each 1 mM), 0.1 M phosphate buffer (pH 7. 4) 400 μl and 50 μl of 30 mM SH compound solution were mixed and incubated at 37 ° C. Incubated. Cysteine, N-acetylcysteine, and GSH were used as SH compounds. After completion of the incubation, glyoxal, methylglyoxal, and 3-deoxyglucosone were converted into quinoxaline derivatives using o-phenylenediamine, and the respective concentrations were measured using high performance liquid chromatography.

  The results are shown in FIG. 23 (cysteine), FIG. 24 (N-acetylcysteine), and FIG. 25 (GSH). It was confirmed that any of the SH compounds had an effect of significantly reducing the concentration with respect to both glyoxal and methylglyoxal.

[Example 12] Trapping effect of albumin on glyoxal, methylglyoxal, 3-deoxyglucosone 50 μl of a mixed solution of glyoxal, methylglyoxal, 3-deoxyglucosone (each 1 mM), 0.1 M phosphate buffer (pH 7.4) ) 400 μl, 50 μl of 100 mg / ml bovine serum albumin solution was mixed and incubated at 37 ° C. After completion of the incubation, glyoxal, methylglyoxal, and 3-deoxyglucosone were converted into quinoxaline derivatives using o-phenylenediamine, and the respective concentrations were measured using high performance liquid chromatography.

  The results are shown in FIG. Bovine serum albumin was confirmed to have an effect of significantly reducing the concentrations of glyoxal and methylglyoxal.

[Example 13] Inhibitory effect of pentosidine formation when SH compound is added to peritoneal dialysis solution and incubated at 37 ° C Peritoneal dialysis solution (PD-4,1.5, manufactured by Baxter) 490 µl, SH compound is 0.1M phosphate buffer 70 μl of solution dissolved in (pH 7.4) and 140 μl of bovine serum albumin dissolved in peritoneal dialysis solution (PD-4, 1.5, manufactured by Baxter) to 30 mg / ml were mixed and incubated at 37 ° C. for 1 week. . As the SH compound, cystein, N-acetylcysteine, GSH, and aminoguanidine were used. After the incubation, 50 μl of 10% trichloroacetic acid was added to 50 μl of the solution and centrifuged to precipitate the protein. The protein was washed with 300 μl of 5% trichloroacetic acid and allowed to dry. Next, after adding 100 μL of 6N HCl and heating at 110 ° C. for 16 hours, pentosidine was quantified by high performance liquid chromatography (T. Miyata et al., 1996, J. Am. Soc. Nephrol., 7: 1198-1206). , T.Miyata et al., 1996, Proc. Natl. Acad. Sci. USA., 93: 2353-2358).

  The results are shown in FIG. It was confirmed that the amount of pentosidine produced was significantly suppressed by the addition of the SH compound.

  According to the present invention, it is possible to easily remove a disorder caused by a carbonyl compound that has plagued a patient in peritoneal dialysis. In the known peritoneal dialysis fluid, the peritoneum of a dialysis patient was always placed in a state of carbonyl stress due to the carbonyl compound leached into the abdominal cavity from the living body by dialysis together with the carbonyl compound produced during the production. On the other hand, in the present invention, the carbonyl compound produced in the peritoneal dialysis solution can be effectively removed, which contributes to improvement of carbonyl stress in dialysis patients. Furthermore, the carbonyl compound leached into the abdominal cavity can be effectively inactivated or removed by introducing the carbonyl compound trapping agent into the abdominal cavity or circulating the dialysate to the carbonyl compound trap cartridge. As described above, the present invention provides a very effective approach as a countermeasure for disorders caused by peritoneal dialysis including peritoneal disorders caused by carbonyl compounds associated with peritoneal dialysis.

  Further, in the present invention, carbonyl compounds derived from heat sterilization and glucose degradation during long-term storage are removed, so that the pH in the neutral range, which has been difficult to prepare pharmacologically due to the conventional glucose degradation, is reduced. It is possible to provide a peritoneal dialysis solution having more physiological peritoneal dialysis therapy.

  The peritoneal dialysis solution of the present invention can be carried out only by a simple operation such as contact or administration with a carbonyl compound trapping agent, and does not require special production equipment. Therefore, the carbonyl compound trapping agent according to the present invention, the peritoneal dialysis fluid using the carbonyl compound trapping agent, and the production method thereof create a new therapeutic concept in peritoneal dialysis treatment.

It is a figure which shows the amount of carbonyl compounds in peritoneal dialysate and peritoneal dialysate drainage. It is the photograph (upper stage) which shows the systematic localization of the carbonyl modification protein in the peritoneum of a peritoneal dialysis patient, and the schematic diagram (lower stage). In the figure, A represents a positive location in the connective tissue under the detached mesothelial cells. B represents the positive part of the thickened blood vessel wall. It is a figure which shows the expression of VEGF mRNA in the mesothelial cell which added glyoxal, methylglyoxal, and 3-deoxyglucosone. Reverse transcription of total RNA extracted from rat mesothelial cell cultures incubated with various concentrations (0, 100, 200, 400 μM) of glyoxal (A), 3-deoxyglucosone (B), and methylglyoxal (C) went. VEGF and G3PDH cDNA were amplified by 30 and 21 cycles of PCR, respectively. Experiments were performed in triplicate to obtain an average. For the mean value of each experiment, the ratio of VEGF mRNA to G3PDH mRNA was calculated. The experiment was performed three times, and the mean ± SD was graphed. * P <0.0005. It is a figure which shows the production of VEGF protein in microvascular endothelial cells by adding methylglyoxal. Human microvascular endothelial cells were cultured in the presence of various concentrations (0, 200, 400 μM) of methylglyoxal, and VEGF protein released into the culture supernatant was quantified by ELISA. Representative results from three experiments are shown. Data are expressed as mean ± range. * P <0.05, ** P <0.01. It is a figure which shows the expression of VEGF mRNA in the endothelial cell which added methylglyoxal. Human endothelial cells were cultured in the presence of various concentrations (0, 100, 200, 400 μM) of methylglyoxal, and a reverse transcription reaction was performed after extraction of total mRNA. VEGF and G3PDH cDNA were amplified by 30 and 21 cycles of PCR, respectively. Experiments were performed in triplicate to obtain an average. For the mean value of each experiment, the ratio of VEGF mRNA to G3PDH mRNA was calculated. The experiment was performed three times, and the mean ± SD was graphed. * P <0.05, ** P <0.005, *** P <0.0001. It is a figure which shows the expression of VEGF mRNA in the rat peritoneal tissue which intraperitoneally administered methylglyoxal daily for 10 days. Expression of VEGF and G3PDH mRNA in the peritoneum was amplified by 28 and 16 cycles of RT-PCR, respectively. Experiments were performed in triplicate to obtain an average. For the mean value of each experiment, the ratio of VEGF mRNA to G3PDH mRNA was calculated. The experiment was performed three times, and the mean ± SD was graphed. * P <0.05. It is a figure showing the carbonyl stress in the abdominal cavity of a peritoneal dialysis patient. It is a figure which shows the addition effect of aminoguanidine with respect to the production of pentosidine by peritoneal dialysis drainage incubation. It is a figure which shows the addition effect of aminoguanidine with respect to protein carbonyl production | generation by peritoneal dialysis drainage incubation. It is a figure which shows the addition effect of aminoguanidine with respect to the amount of carbonyl compounds in the peritoneal dialysis (CAPD) drainage of three peritoneal dialysis patients (patient I, patient S, and patient K). It is a figure which shows the addition effect of aminoguanidine with respect to 5-HMF production | generation in the peritoneal dialysate in an acidic environment. It is a figure which shows the addition effect of aminoguanidine with respect to 5-HMF production | generation in the peritoneal dialysate in a neutral environment. It is a figure which shows the addition effect of aminoguanidine with respect to the amount of carbonyl compounds in the peritoneal dialysate in an acidic and neutral environment. It is a figure which shows the pentosidine production | generation suppression effect by carbonyl compound trap bead addition to a peritoneal dialysate. It is a figure which shows the carbonyl compound removal effect by carbonyl compound trap bead addition to a peritoneal dialysate. It is a figure which shows the carbonyl compound removal effect by activated carbon addition to a dicarbonyl solution. It is a figure which shows the carbonyl compound removal effect by activated carbon addition to a peritoneal dialysate. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when using guanidine. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when metformin (Metformin) is used for a biguanide agent. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when buformin (Buformin) is used for a biguanide agent. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when using phenformin (Phenformin) for a biguanide agent. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when aminoguanidine is used. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when cysteine is used for SH compound. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when N-acetylcysteine is used for SH compound. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when GSH is used for SH compound. It is a figure which shows the trap effect with respect to glyoxal, methylglyoxal, and 3-deoxyglucosone when albumin is used for SH compound. It is a figure which shows the production | generation suppression effect of a pentosidine when an SH compound is added to a peritoneal dialysate.

Claims (12)

An intraperitoneal carbonyl stress state ameliorating agent in peritoneal dialysis containing a carbonyl compound trapping agent as an active ingredient. The carbonyl stress state improving agent according to claim 1, wherein the carbonyl compound trapping agent is immobilized on an insoluble carrier. The carbonyl stress state-improving agent according to claim 1, wherein the carbonyl compound trapping agent is for mixing with a peritoneal dialysis solution. The carbonyl stress according to any one of claims 1 to 3, wherein the carbonyl compound trapping agent is a compound selected from the group consisting of aminoguanidine, pyridoxamine, hydrazine, biguanide compounds, SH group-containing compounds, or derivatives thereof. Condition improver. The carbonyl stress state improving agent according to any one of claims 1 to 3, wherein the carbonyl compound trapping agent is a Maillard reaction inhibitor. The carbonyl stress state-improving agent according to claim 1, wherein the carbonyl compound trapping agent is a compound insoluble in a peritoneal dialysis solution capable of adsorbing a carbonyl compound. A cartridge for trapping a carbonyl compound in a peritoneal dialysis solution filled with the carbonyl compound trapping agent according to claim 2 and / or 6. A method for preparing a peritoneal dialysate with a reduced carbonyl compound content, comprising the step of passing the peritoneal dialysate through the cartridge for trapping a carbonyl compound according to claim 7. A method for preparing a peritoneal dialysis solution having a reduced carbonyl compound content, comprising the following step.
a) a step of bringing the carbonyl compound trapping agent according to claim 2 and / or 6 into contact with a peritoneal dialysis solution; and b) a step of separating the carbonyl compound trapping agent from the peritoneal dialysis solution. A peritoneal dialysis solution containing a carbonyl compound trapping agent. In the peritoneal dialysis solution accommodated in the fractionated container consisting of the first chamber and the second chamber, the reducing sugar is accommodated in the first chamber, and the carbonyl compound trapping agent is accommodated in the second chamber. The peritoneal dialysis solution according to claim 10. The peritoneal dialysis solution according to claim 10, wherein the carbonyl compound trapping agent is for intraperitoneal administration together with the peritoneal dialysis solution.